organization · Reporting owner
Aequanimitas Limited Partnership
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Rani Therapeutics Holdings, Inc.
Report date November 24, 2023 · Filed December 08, 2023
Jointly reported with Quiroga Cortes Isidoro Alfonso
Section 16 reporting ended · disclosed 2023-12-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectShares indirectly held through Aequanimitas Limited Partnership | 8,400 |
Reported balance
After 2023-11-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-11-24 · Sale · Disposed 5,265,165 · Balance 8,400 F1: The Reporting Person sold 5,265,165 shares of the Issuer's Class A Common Stock in a private secondary offering that was priced at the prevailing market price. F2: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas Limited Partnership ("Aequanimitas") as its general partner with the power to manage Aequanimitas. Quiroga Cortes is the sole limited partner of Aequanimitas. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person sold 5,265,165 shares of the Issuer's Class A Common Stock in a private secondary offering that was priced at the prevailing market price.
F2: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas Limited Partnership ("Aequanimitas") as its general partner with the power to manage Aequanimitas. Quiroga Cortes is the sole limited partner of Aequanimitas.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 24, 2023 Filed Dec 8, 2023 16:29 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | SaleClass A Common Stock | 5,265,165 | $2.01 | $10,582,981.65 |
DisclosureSEC source: 0001104659-23-124723 · tm2332512-1_4seq1.xml · nonDerivative · entry 1 Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner Aequanimitas Limited Partnership · CIK 0001953625 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership Disclosed balance after: 8,400 F1 · kind: The Reporting Person sold 5,265,165 shares of the Issuer's Class A Common Stock in a private secondary offering that was priced at the prevailing market price. F2 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas Limited Partnership ("Aequanimitas") as its general partner with the power to manage Aequanimitas. Quiroga Cortes is the sole limited partner of Aequanimitas. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 20:06 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 8,400 | $6.03 | $50,616.72 |
DisclosureSEC source: 0001104659-23-000497 · tm2231865-8_4seq1.xml · nonDerivative · entry 1 Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner Aequanimitas Limited Partnership · CIK 0001953625 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership Disclosed balance after: 5,271,378 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.84 to $6.20 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas Limited Partnership ("Aequanimitas") as its general partner with the power to manage Aequanimitas. Quiroga Cortes is the sole limited partner of Aequanimitas. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 17:06 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 15,192 | $6.90 | $104,794.42 |
DisclosureSEC source: 0001104659-22-115484 · tm2229846-1_4seq1.xml · nonDerivative · entry 1 Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner Aequanimitas Limited Partnership · CIK 0001953625 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership Disclosed balance after: 5,262,978 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.42 to $7.00 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas Limited Partnership ("Aequanimitas") as its general partner with the power to manage Aequanimitas. Quiroga Cortes is the sole limited partner of Aequanimitas. Read SEC document |
| November 02, 2022 Filed Nov 7, 2022 17:08 UTC Amendment | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 25,197 | $6.31 | $158,955.27 |
DisclosureSEC source: 0001104659-22-115487 · tm2229846-2_4aseq1.xml · nonDerivative · entry 3 Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner Aequanimitas Limited Partnership · CIK 0001953625 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership Disclosed balance after: 5,247,786 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.50 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. F1 · ownership.nature: This amendment to Isidoro Alfonso Quiroga Cortes' Form 4, originally filed with the SEC on November 2, 2022 (the "Original Form 4"), is being filed to include Aequanimitas Limited Partnership ("Aequanimitas") as a Reporting Person under the Original Form 4. F5 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas as its general partner with the power to manage Aequanimitas. Isidoro Alfonso Quiroga Cortes is the sole limited partner of Aequanimitas. Read SEC document |
| November 01, 2022 Filed Nov 7, 2022 17:08 UTC Amendment | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 3,768 | $5.98 | $22,533.39 |
DisclosureSEC source: 0001104659-22-115487 · tm2229846-2_4aseq1.xml · nonDerivative · entry 2 Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner Aequanimitas Limited Partnership · CIK 0001953625 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership Disclosed balance after: 5,222,589 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.96 to $6.22 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. F1 · ownership.nature: This amendment to Isidoro Alfonso Quiroga Cortes' Form 4, originally filed with the SEC on November 2, 2022 (the "Original Form 4"), is being filed to include Aequanimitas Limited Partnership ("Aequanimitas") as a Reporting Person under the Original Form 4. F5 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas as its general partner with the power to manage Aequanimitas. Isidoro Alfonso Quiroga Cortes is the sole limited partner of Aequanimitas. Read SEC document |
| October 31, 2022 Filed Nov 7, 2022 17:08 UTC Amendment | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 16,523 | $6.11 | $100,977.01 |
DisclosureSEC source: 0001104659-22-115487 · tm2229846-2_4aseq1.xml · nonDerivative · entry 1 Quiroga Cortes Isidoro Alfonso · CIK 0001854578 · 10% owner Aequanimitas Limited Partnership · CIK 0001953625 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership Disclosed balance after: 5,218,821 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.98 to $6.14 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. F1 · ownership.nature: This amendment to Isidoro Alfonso Quiroga Cortes' Form 4, originally filed with the SEC on November 2, 2022 (the "Original Form 4"), is being filed to include Aequanimitas Limited Partnership ("Aequanimitas") as a Reporting Person under the Original Form 4. F5 · ownership.nature: Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas as its general partner with the power to manage Aequanimitas. Isidoro Alfonso Quiroga Cortes is the sole limited partner of Aequanimitas. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.